

Pediatric Type 1 Diabetes Care in Indonesia: A Review of Current Challenges and Practice

Muhammad Fauzi^{1,2}, Ghaisani Fadiana^{2,4}, Dhiya Nadira⁵, Angela⁶, Helena Arnetta Puteri⁵, Aman Pulungan^{*2,4}

¹Department of Child Health, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya, Indonesia

²Indonesian Pediatric Society, Jakarta, Indonesia

³Changing Diabetes in Children Indonesia, Jakarta, Indonesia

⁴Department of Child Health, Universitas Indonesia, Jakarta, Indonesia

⁵Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

⁶Faculty of Medicine, Universitas Kristen Krida Wacana, Jakarta, Indonesia

Abstract

Type 1 Diabetes Mellitus (T1DM) is a chronic condition requiring lifelong management that affects a large number of children and adolescents globally. While diabetes care has improved over the years, low-middle income countries (LMIC) like Indonesia still struggle to achieve optimal diabetes care due to limited access to healthcare professionals, insulin, diabetes technologies, and self-monitoring blood glucose (SMBG) devices. Data from the Indonesian Pediatric Society registry has reflected a stark increase in the number of children with T1DM, with the current prevalence significantly concentrated on Java Island and a noticeable underreporting in rural regions. Another major challenge is the uneven distribution of pediatric endocrinologists, resulting in a low specialist-to-patient ratio. This imbalance, coupled with inadequate access to comprehensive diabetes care, complicates effective T1DM management. While the national insurance covers a portion of costs associated with T1DM care, vital aspects of T1DM management including SMBG devices are still not covered, resulting in significant financial burden to families. Access to diabetes technologies that improve glycemic control and quality of life of patients is also still largely limited. This paper evaluates the current state and future needs for insulin and SMBG in Indonesia, emphasizing the necessity of strategic interventions to improve access and quality of diabetes care.

Keywords: Pediatric, type 1 diabetes, challenges, practice

Aman B Pulungan, M.D., Ph.D., FAAP, FRCPI (Hon.), Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo General Hospital, Jl. Diponegoro no 71, Jakarta 10430, Indonesia

amanpulungan@mac.com

<https://orcid.org/0000-0003-4895-4105>

05.09.2024

27.11.2024

Epub: 27.11.2024

1. Introduction

Widely regarded as one of the most common non-communicable diseases (NCD) in children, type 1 diabetes mellitus (T1DM) is a chronic condition that requires comprehensive and lifelong management. Insulin and self-monitoring of blood glucose are integral components of successful T1DM management. While access and availability of diabetes technologies, insulin, and SMBG devices may be available in most high-income countries, low and middle-income countries like Indonesia still struggle to provide attainable access to optimum diabetes care [1–3]. As Indonesia works towards achieving Sustainable Development Goals (SDG) target 3.4 to reduce premature mortality associated with NCDs, concerted efforts must be made to ensure the availability of insulin and other diabetes technologies. This paper evaluates the current situation and prospective needs for insulin and self-monitoring blood glucose in Indonesia.

2. Epidemiology of T1DM in Indonesia

According to Changing Diabetes in Children (CDiC) Indonesia database in January 2024, there are 1210 children and adolescents aged 0-25 years that have been diagnosed with T1DM [4]. Based on the CDiC Indonesia registry, the highest population of T1DM in Indonesia is found on the island of Java, especially in Jakarta, and it is more commonly found in girls. However, this can be attributed to low reporting and case finding in rural areas outside of Java Island. The population of T1DM in Indonesia until January 2024 is shown in **Figure 1**. Based on the CDiC registry, the age-based population of T1DM is mainly between 11 and 15 years old. **Figure 2** shows the age-based population. The data reported in this study is lower than that of most countries. This may be because the prevalence reported is hospital-based, whereby these are patients that are reported by each individual pediatric endocrinologist who manages them. Therefore, the number of children and adolescents living with T1DM is believed to be underreported.

3. Pediatric Endocrinologist in Indonesia

According to the Indonesian Pediatric Society (IPS) database, in 2024, there are 39 pediatric endocrinologists whose practices are located in 18 provinces (out of 38 provinces in Indonesia), reflecting the uneven distribution of pediatric endocrinologists in Indonesia [5]. As of 2023, Indonesia has 84,198,626 children, while 1,210 children and adolescents aged 0-25 years are diagnosed with T1DM [6,7]. This means that the ratio is 1:134 pediatric endocrinologists to children with T1DM and 1:2,000,000 endocrinologists for the children population. This signifies the low ratio of pediatric endocrinologists to the population of children in Indonesia. In LIC, such as Ethiopia, the ratio is 1:40,000,000 pediatric endocrinologists for the children population [8]. Along with the increase in the prevalence of children diagnosed with T1DM in Indonesia, this shall lead to increased demand for endocrine care. This factor predominantly affects the demand for more pediatric endocrinologists.

In Indonesia, T1DM patients are mainly under pediatric endocrinologist care. While in other countries, T1DM is also managed by a comprehensive team. We see a trend where LMIC's approach to T1DM care is centered around pediatric endocrinologists, while HIC already has a dedicated interprofessional team for T1DM care. In Pulungan et al., data was from 25 countries in six regions; only 24% of respondents stated that pediatricians are the chief healthcare professionals responsible for T1DM care. This study also further elaborates on the need for a comprehensive team of medical care for T1DM in 36% of respondents [1]. A persistent issue in LMIC is the insufficient number and uneven distribution of qualified healthcare professionals (HCPs). The absence of adequate technical guidance, training initiatives, and financial support for these programs exacerbates this challenge [9].

Pediatric endocrinologists often advocate for their patients, particularly in environments lacking universal healthcare coverage. The Think Tank Group outlines a 7-step cascade to assist these professionals in their advocacy role. The cascade begins with identifying the target population and progresses through ensuring service contact coverage, assessing input-adjusted coverage, intervention coverage, and quality-adjusted coverage. It further evaluates user adherence and outcome-adjusted coverage to ensure optimal care and desired health outcomes.

This framework provides a structured approach for pediatric endocrinologists to optimize support for patients and families dealing with T1DM, and it can be adapted to various patient groups [10].

4. Insulin supply in Indonesia and its importance

Since its discovery in 1921, insulin has been the core life-saving treatment for diabetes. It is the cornerstone of optimal blood sugar control in countries with limited resources [11]. Approaching normoglycemia is the goal of T1DM therapy, where the condition can be achieved using insulin. Clinical use of insulin is remarkably complex, and optimal glycemic control can be challenging to achieve and maintain. There is rarely a treatment regimen that always applies to all people because of the dynamic nature of growth, development, and hormonal changes during childhood and adolescence [12].

Insulin therapy plays a crucial role in the management of T1DM. A solid understanding of these insulin therapy methods is essential for effective management. Studies conducted by Saw et al. have highlighted several shortcomings, including a low level of knowledge regarding insulin therapy. Saw et al. recommended enhancing and monitoring T1DM management training for healthcare providers across various sectors [11].

Children and adolescents with T1DM require multiple insulin injections in a single day and often use a combination of fast-acting, short-acting, medium-acting, or long-acting insulin to achieve optimal blood sugar control. New insulin analogs and diabetes technology tools have transformed insulin treatment during the past few decades. Insulin pens become a popular insulin delivery modality in young people with diabetes due to their ease of use and increased dosing accuracy compared to insulin delivery. In some countries, there are insulin pens connected with smart phone applications and continuous glucose monitoring (CGM), allowing pen users access to benefits such as data collection, alerts and reminders, and dosing calculators that take insulin on board into account [13].

According to the PrimaKu and CDiC database in January 2024, children and adolescents with T1DM use three groups of insulin: basal, bolus, and premix [14]. The types of basal insulin used by patients are Levemir[®], Lantus[®], Ezelin[®], and Sansulin[®]. The types of insulin bolus used in Indonesia are Apidra[®], Novorapid[®], Humalog[®], and Lispro[®]. Premix insulin used in Indonesia is Humalog mix 25[®], Humalog mix 50[®], and Novomix[®].

Based on the CDiC Indonesia registry, more than 50% of 1,210 patients used Novorapid[®] in their daily blood sugar management [14]. Novorapid[®] is commonly used in blood sugar management settings, often combined with basal and premix insulin therapies. The most frequently utilized insulin combination is the basal bolus combination.

The daily insulin dose for patients with type 1 diabetes mellitus is empirically recommended to be between 0.7 and 1.2 units per kilogram of body weight per day [12]. The estimated national insulin requirement for children with T1DM is calculated based on the average daily dose and the average body weight of registered patients, who are approximately 12.3 years old. Therefore, age limits of 12 and 13 years are utilized. The lower limit corresponds to the two-digit P50 rounding of the weight curve for 12-years-old boys, which is 35 kg (rounded up from 34.81 kg). The upper limit is based on the two-digit P50 rounding of the weight curve for 13-year-old girls, resulting in 40 kg (rounded up from 39.51 kg). The national growth curve used for this calculation is the Indonesian National Synthetic Growth Chart developed by Pulungan et al. in 2018 [15].

The calculation of the national insulin adequacy requirement involves estimating twice the number of patients currently registered in the IPS Endocrinology Working Group-CDiC Indonesia joint registry, which is almost 20% of the number reported by the International Diabetes Federation (IDF) in 2022 [16]. Calculation of the national insulin requirement can be seen in Table 1. Most patients use a basal bolus regimen with proportion 50:50. This proportion varies from what is generally utilized in other countries as children in Indonesia tend to not inject insulin whilst at school. Therefore, most pediatric endocrinologists opt to increase the basal insulin dose to compensate for not injecting during school hours. This highlights an existing need for greater support in schools as well. Whereas insulin availability is generally in pen and cartridge form with a strength of 1 ml containing 100 insulin units, 300 units per-cartridge. Based on Table 1 with minimal and maximal insulin dose, calculation of the national insulin requirement for children and adolescents with T1DM in cartridges can be simplified as Table 2.

Insulin is a critical part of T1DM care. First introduced in 1962, insulin pumps have been largely instrumental in improving glycemic control in pediatric T1DM patients, with early studies already demonstrating a clear benefit towards improving glycemic control with less fluctuations in glucose levels and lower incidence of hypoglycemia [17]. As technology rapidly progresses, new hybrid closed loop system integrate CGM systems with an insulin pump and take it a step further to offer automated insulin delivery in response to blood glucose trends. Studies conducted in high-income countries have shown increased time-in-range, improved HbA1c and a decrease in hypoglycemic events. Currently, insulin pumps are only available to a handful of those capable of paying out of pocket or have access to private insurance that provides coverage. They are not provided by most insurance providers including the national health insurance. Our data estimates that insulin pumps are only used by less than 2% of T1DM pediatric patients in Indonesia.

5. Self-Monitoring Blood Glucose (SMBG) in Indonesia

Routine SMBG helps patients to adjust their insulin dose with food intake. Therefore, it also enables patients to correct their blood glucose when it is out of the target range. Well-controlled SMBG further contributes to HbA1c levels. SMBG is also crucial for patients when performing sports to adjust insulin dose before, during, and after physical activity to avoid the risk of hypoglycemia. Monitoring SMBG in cases where patients are sick is also crucial [18].

The frequency of SMBG varies according to individuals and the availability of testing devices and strips. It also depends on patients' and caregivers' ability to recognize early signs of T1D emergencies and conduct a blood glucose check. To optimize glycemic control, SMBG is recommended to be done 6-10 times a day [19]. There has not been a study that compiles the mean HbA1c levels for children nationally, data are limited to each center. As in Jakarta, the average HbA1c level is around 12.5%, whereas in Surabaya, the average HbA1c level is 10.7% [20].

In Indonesia, finger-stick blood glucose monitoring is the most widely used method to check patients' glucose levels periodically. Similar to the global data, this method is widely used in most countries, while CGM is only available in a mere 1/3 of respondent countries [1]. Data has shown that CGM is superior to the finger stick method for several reasons: 1) CGM is associated with lower HbA1c, 2) the finger stick method requires patients' compliance and awareness [21,22]. CDiC data stated that 53% of registered patients regularly check their SMBG, with half of them infrequently checking their SMBG. Studies have shown that CGM is cost-effective in decreasing short-term and long-term complications and yields lower HbA1c control in patients compared to finger stick testing [21–23]. Unfortunately, SMBG devices and glucometer strips are not covered by the national health insurance, therefore making this a challenge.

CGM systems are more flexible than conventional finger-prick glucose tests, especially beneficial for patients on intensive insulin therapy, reducing discomfort and allowing for easier glucose monitoring. Despite being registered in the Food and Drug Supervisory Agency, the use of CGM has not been widely established in Indonesia as payment has to be done entirely out of pocket. It is not covered in the national insurance scheme, which the vast majority of T1DM patients in Indonesia rely on. While there are some private insurance and company insurance that covers CGM, it is important to note that access to such insurance may be limited to those who can afford those private insurance. Current efforts to improve diabetes care in Indonesia have yet to reach the improvement of access to diabetes technologies, as efforts are currently being directed towards the training of healthcare professionals and expansion of access and availability to basic diabetes care such as SMBG devices and insulin.

6. Current situation and challenges in Indonesia

“Children are not little adults” is a theme emphasized by the American Diabetes Association in their 2018 position statement on Type 1 Diabetes in Children and Adolescents [24]. With its distinctive pathophysiology, epidemiology, psychosocial challenges, and developmental considerations, diabetes in children is vastly different from adult diabetes [25]. The pediatric and adolescent period comprise of years of rapid growth and formative development. Coupled with the challenges that naturally occur during those years, children and adolescents living with T1DM have the added challenge of accommodating T1DM as part of their day-to-day lives [24]. This includes regular insulin injections, blood glucose monitoring, nutritional planning, physical activity and concerns of high/low blood glucose [26]. The importance of good T1DM management cannot be overstated with its direct association with glycemic control, improvement in quality of life and protection from long-term diabetes-associated complications [27].

To achieve optimal T1DM management, patients and families must be supported with adequate means to attain access to treatment including insulin, SMBG devices and monitoring examinations, comprehensive education and psychosocial support. Introduced in 2014, the main health insurance scheme available to Indonesian citizens is *Jaminan Kesehatan Nasional (JKN)* [28]. Under this scheme, T1DM patients are able to access a monthly supply of basal and prandial insulin based on the indicated doses, 90 pieces of needle and alcohol swab, as well as a HbA1c examination every three months. Insulin is available in all hospitals but not primary health centers. Therefore, most patients diagnosed with T1DM are able to access this basic care if they are enrolled in the national health insurance. However, SMBG devices such as glucometers and glucose strips are not covered by the national insurance. Examination of diabetes-related antibodies are not routinely conducted in Indonesia, both in academic medical institutes as well as private practice. This is only available in a limited selection of centers. However, in 2024, pediatric endocrinologists are currently advocating for the examination of diabetes-related antibodies. This condition is equivalent with examinations such as C-peptide examination and insulin autoantibodies are not routine examinations conducted but are available if paid out-of-pocket in several major health centers. Essential treatment in T1DM emergency, such as Glucagon, is currently not under the coverage of JKN. Devices like insulin pumps and CGM tremendously improved diabetes management. However, access and availability to such devices in Indonesia still need to be improved even in academic medical institutes where most patients rely on the national insurance.

The cost of SMBG devices in Indonesia range from Rp 300,000 to Rp 600,000 (19.21-38.40 USD), with a pack of 25 glucose strips ranging from Rp 60,000 to Rp 120,000 (3.84-7.68 USD). With a minimum requirement of four glucose tests a day and a recommended number of six tests per day, this totals up to Rp. 600,000 (38.40 USD) per month if families were forced to pay out of pocket. In a country where the monthly average household income is Rp. 3,178,227 (203.52USD) in 2023, this places additional financial burden on patients and families [29]. While insulin is generally covered by the national health insurance, there are still patients who have to pay out-of-pocket for insulin. It is not uncommon for patients to purchase insulin out-of-pocket as they found that the supply covered by the national health insurance is insufficient or with the intention of reducing the need for monthly visits therefore reducing transportation costs and inconvenience associated with hospital visits (day off from work/school, having other children to take care of). When access to insulin and SMBG devices are threatened, so is the overall management and glycemic control. Patients are also at higher risk of experiencing life-threatening complications [30,31].

One of the efforts in alleviating the challenges T1DM care equity is CDiC Indonesia. CDiC Indonesia is a public-private partnership focused on improving access to T1DM care [31]. One of their programs includes providing blood glucose strips to patients registered in their program. T1DM patients between the age of 0 to 25 years old are eligible to receive four glucose strips a day and monthly supplies of glucose strips are delivered to patients' homes.

Another prominent multisectoral partnership include existing national health mobile applications and information systems, namely PrimaKu and SatuSehat. PrimaKu is an application developed in collaboration with the Ministry of Health, the Indonesian Pediatric Society (IDAI), and the National Population and Family Planning Board (BKKBN), in the form of a mobile application used by parents across Indonesia to monitor their children's growth and development [32]. In 2023, PrimaKu was updated to include a Diabetes Diary feature, allowing T1DM patients to either connect their glucometers to PrimaKu for automatic syncing or manually input their SMBG results, which sync directly with a glucometer. The Diabetes Diary is not limited for use by only pediatric T1DM patients. As of November 2024, there are 1408 people registered to use the diabetes diary.

As part of an effort to integrate health information systems and to improve efficiency, PrimaKu has since launched a collaboration with SatuSehat. SatuSehat is a national initiative by the Ministry of Health that integrates patient medical record data at health facilities into one Indonesia Health Services (IHS) [33]. While Indonesia has seen substantial growth towards digitalization, not all patients are able to benefit from this, as there are still patients with limited access to mobile devices and internet. For these patients, SMBG is recorded manually using pen and paper.

As previously stated, it is highly likely that the prevalence of T1DM reported in this study only reflects the tip of the iceberg. National databases are based on hospital-based data reported to CDiC or the Endocrinology Working Group of the Indonesian Pediatric Society. With the false perception that the prevalence of T1DM in Indonesia is low, this contributes to the poor understanding and awareness of the general public as well as health care professionals in Indonesia. In turn, the lack of awareness and knowledge of health care professionals also leads to cases being underdiagnosed and misdiagnosed. However, in recent years, through advocacy and public campaigns conducted by organizations like CDiC and the Endocrinology Working Group of IPS, this has started to change. One of them being a national training initiated in collaboration with the Ministry of Health to train healthcare professionals on how to diagnose and manage diabetes in both children and adults.

While several major government hospitals are working towards establishing diabetes clinics, this is still widely unavailable in Indonesia. International recommendations have highlighted the importance of a multidisciplinary diabetes team consisting of a pediatric endocrinologist, dietitian, a diabetes nurse educator and a mental health professional [34]. Multidisciplinary care is hampered as Indonesia lacks the number and quality of training of healthcare professionals [35,36]. While several major hospitals may conduct in house training, training of healthcare professionals in Indonesia is largely supported by organizations like CDiC Indonesia. CDiC Indonesia routinely conducts basic and advanced training regarding the diagnosis and management of T1DM in children and adolescents free-of-charge and open to healthcare professionals nationally. As access to a multidisciplinary team in Indonesia is still limited, a lot of the burden of diabetes education is placed on pediatric endocrinologists, pediatricians or residents working in the endocrinology clinic of government teaching hospitals. The limited number of healthcare professionals supporting the diabetes management of T1DM patients translates to less guidance potentially provided to patients, including support in insulin dose adjustments or management of acute conditions. This contrasts with the care available in a majority of high-income countries, such as the provision of 24-hour emergency call centers, a help center that answers queries and provides suggestions via email or call, as well as a diabetes clinic system that links CGM data to diabetes clinics enabling remote monitoring by the diabetes team [36].

7. Conclusion

In conclusion, the landscape of T1DM management in Indonesia reveals a multifaceted challenge requiring comprehensive strategies to address. Despite the concerted efforts of organizations like CDiC Indonesia and advancements in insulin therapy and diabetes technology, significant gaps persist in access to care and resources. The epidemiological data underscores the growing burden of T1DM among children and adolescents, magnified by the uneven distribution of pediatric endocrinologists and limited access to insulin and SMBG devices. The current reliance on pediatric endocrinologists for T1DM care underscores the need for a more comprehensive, multidisciplinary approach to management, as seen in high-income countries. Furthermore, while the national health insurance provides some coverage for insulin,

essential SMBG devices remain largely uncovered, posing financial burdens on families and threatening overall glycemic control. Addressing these challenges necessitates not only improvements in healthcare infrastructure and access but also comprehensive education and support for patients and families. Collaboration between public and private sectors, along with expanded training programs for healthcare professionals, will be pivotal in enhancing T1DM management and improving outcomes for affected individuals in Indonesia.

References

1. Pulungan AB, de Beaufort C, Ratnasari AF, Puteri HA, Lewis-Watts L, Bhutta ZA. Availability and access to pediatric diabetes care: a global descriptive study. *Clinical Pediatric Endocrinology*. 2023;32(3).
2. Klatman EL, Ogle GD. Access to insulin delivery devices and glycated haemoglobin in lower-income countries. *World J Diabetes*. 2020;11(8).
3. Saiyed M, Hasnani D, Alonso GT, Richmond E, Besançon S, Cotterill A, et al. Worldwide differences in childhood type 1 diabetes: The SWEET experience. *Pediatr Diabetes*. 2021;22(2).
4. Changing Diabetes in Children Indonesia. Patient Registry. Jakarta; 2024.
5. Indonesian Pediatric Society. Database of the Endocrinology Working Group. 2023.
6. Endocrinology Working Group of the Indonesian Pediatric Society. National pediatric diabetes registry. Jakarta; 2024.
7. Department of Economic and Social Affairs PDUN. World Population Prospects 2024. United Nations. 2024.
8. Federal Ministry of Health. Health and Health Related Indicators. Ethiopia; 2011.
9. Mills A. Health Care Systems in Low- and Middle-Income Countries. *New England Journal of Medicine*. 2014;370(6).
10. Chanoine JP, Stafford D. Global Health for the Paediatric Endocrinologist. *Yearbook of Paediatric Endocrinology*. 2023;
11. Sow A, Boiro D, Sow PS, Niang B, Mbaye A, Barrage AL, et al. Insulin therapy in childhood type 1 diabetes: Knowledge and practice in Senegal. *Archives de Pediatrie*. 2021;28(4).
12. Cengiz E, Danne T, Ahmad T, Ayyavoo A, Beran D, Ehtisham S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes. *Pediatr Diabetes*. 2022;23(8).
13. Sherr JL, Schoelwer M, Dos Santos TJ, Reddy L, Biester T, Galderisi A, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. *Pediatr Diabetes*. 2022;23(8).
14. Changing Diabetes in Children Indonesia. Insulin data 2024. Jakarta; 2024.
15. Aman B, Pulungan., et al. "Indonesian National Synthetic Growth Charts." *Acta Scientific Paediatrics*. 2018;1.
16. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract*. 2022;183.
17. Al-Beltagi M, Saeed NK, Bediwy AS, Elbeltagi R. Insulin pumps in children - a systematic review. *World J Clin Pediatr*. 2022;11(6).
18. Marks BE, Wolfsdorf JL. Monitoring of Pediatric Type 1 Diabetes. *Front Endocrinol (Lausanne)*. 2020;11.
19. Tauschmann M, Forlenza G, Hood K, Cardona-Hernandez R, Giani E, Hendrieckx C, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. *Pediatr Diabetes*. 2022;23(8).
20. Rochmah N, Hisbiyah Y, Perwitasari RK, Rosaningrum J, Wicaksono G, Kusumastuti NP, et al. Quality of Life, Medication Adherence, and Glycemic Control in Type 1 Diabetes Mellitus Children with Basal Bolus Regimen During COVID-19 in Limited Resources Setting. *Journal of Comprehensive Pediatrics*. 2023;14(3).
21. Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. *Diabetes Technol Ther*. 2016;18(S2).
22. Jiao Y, Lin R, Hua X, Churilov L, Gaca MJ, James S, et al. A systematic review: Cost-effectiveness of continuous glucose monitoring compared to self-monitoring of blood glucose in type 1 diabetes. Vol. 5, *Endocrinology, Diabetes and Metabolism*. 2022.
23. Funtanilla VD, Caliendo T, Hilas O. Continuous glucose monitoring: A review of available systems. *P and T*. 2019;44(9).
24. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 diabetes in children and adolescents: A position statement by the American Diabetes Association. *Diabetes Care*. 2018;41(9).
25. Wherrett DK, Chiang JL, Delamater AM, Dimeglio LA, Gitelman SE, Gottlieb PA, et al. Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. *Diabetes Care*. 2015;38(10).
26. Adu MD, Malabu UH, Malau-Aduli AEO, Malau-Aduli BS. Enablers and barriers to effective diabetes self-management: A multi-national investigation. *PLoS One*. 2019;14(6).
27. Himawan IW, Pulungan AB, Tridjaja B, Batubara JRL. Komplikasi Jangka Pendek dan Jangka Panjang Diabetes Mellitus Tipe 1. *Sari Pediatri*. 2016;10(6).
28. Agustina R, Dartanto T, Sitompul R, Susiloretni KA, Suparmi, Achadi EL, et al. Universal health coverage in Indonesia: concept, progress, and challenges. *The Lancet*. 2019;393(10166).
29. Indonesia BPS. Rata-Rata Upah/Gaji (Rupiah), 2023. Badan Pusat Statistik. 2024.
30. Willner S, Whittlemore R, Keene D. "Life or death": Experiences of insulin insecurity among adults with type 1 diabetes in the United States. *SSM Popul Health*. 2020;11.
31. Novo Nordisk. Changing diabetes in children programme for children with type 1 diabetes. Novo Nordisk. 2024.
32. PrimaKu: Pelopor Aplikasi Tumbuh Kembang Anak. 2024.
33. SATUSEHAT: Ekosistem Data Kesehatan Indonesia. 2024.
34. Lindholm Olander A, DeAbreu M, Greene S, Haugstvedt A, Lange K, Majaliwa ES, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes education in children and adolescents. *Pediatr Diabetes*. 2022;23(8).
35. Soewondo P, Ferrario A, Tahapary DL. Challenges in diabetes management in Indonesia: A literature review. *Global Health*. 2013;9(1).
36. Limbert C, Tinti D, Malik F, Kosteria I, Messer L, Jalaludin YM, et al. ISPAD Clinical Practice Consensus Guidelines 2022: The delivery of ambulatory diabetes care to children and adolescents with diabetes. *Pediatr Diabetes*. 2022;23(8).

Figure 1. Distribution of type 1 diabetes mellitus in Indonesia until January 2024






Figure 2. Dis



*Age Group (Years Old)

Figure 3. Distribution of Pediatric Endocrinologists in Indonesia



Created with mapchart.net

Table 1. Calculation of the National Insulin Needs

Body weight (Kg)	Individual daily dose (unit/KgBW)		Number of patients	Monthly needs		Yearly needs	
	0.7	1.2		Minimal (Unit)	Maximal (Unit)	Minimal (Unit)	Maximal (Unit)
35	24.5	42	2204	1,766,940	3,029,040	21,203,280	36,348,480
40	28	48		2,019,360	3,461,760	24,232,320	41,541,120

Kg = Kilograms, KgBW = Kilogram Body Weight

Table 2. Forecast of National T1DM Insulin Cartridge Requirement

Insulin	Monthly needs (Cartridge)		Yearly needs (Cartridge)	
	Minimal	Maximal	Minimal	Maksimal
Basal	2,944.9	5,769.6	35,338.8	69,235.2
Bolus	2,944.9	5,769.6	35,338.8	69,235.2
Total	5,889.8	11,539.2	70,677.6	138,470.4